ELGX Endologix Inc

Endologix, Inc. (Nasdaq:ELGX) today announced that two presentations at the 32nd Annual VEITH symposium(TM) will highlight the Company's minimally invasive treatment for abdominal aortic aneurysms (AAA), the Powerlink(R) System. The VEITH symposium is being held November 17-20 at the Sheraton New York Hotel and Towers in New York City. The two presentations discussing the Powerlink System include: -- "Transrenal Stent Placement in EVAR is not Harmful to the Kidneys: A 4-Year Controlled Study with the Powerlink Endograft," which will be presented by Jeffrey P. Carpenter, M.D., Professor of Surgery at the University of Pennsylvania School of Medicine and Director of the Vascular Laboratory at the Hospital of the University of Pennsylvania. Dr. Carpenter's presentation will discuss a comparison of the Powerlink Infrarenal Bifurcated System and the Powerlink Suprarenal Bifurcated System and any difference of the devices on renal function. -- "Factors Contributing to True and Apparent Graft Migration After EVAR with the Powerlink Endograft: The Importance of AAA Sac Remodeling," which will be presented by Rodney A. White, M.D., Professor of Surgery at UCLA School of Medicine and Chief of Vascular Surgery at Harbor-UCLA Medical Center. Dr. White's presentation will include 4-year follow-up data from Endologix's pivotal clinical trial with the Powerlink. The VEITH symposium provides a forum for presentations by renowned vascular surgeons with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques. Additional information is available at www.veithsymposium.org. About Endologix Endologix, Inc. develops and manufactures minimally invasive treatments for vascular diseases. Endologix's Powerlink System is an endoluminal stent graft (ELG) for treating abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it the thirteenth leading cause of death in the U.S. In October 2004, Endologix received approval to market the Powerlink in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com.